← FDA DRUG APPROVALS

FDA ANDA · ANDA204237

RABEPRAZOLE SODIUM

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA204237
TYPE
ANDA
ORIGINAL APPROVAL
2015-11-18
LATEST ACTION
2026-06-05
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

RABEPRAZOLE SODIUMPrescription
RABEPRAZOLE SODIUM 20MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2026-06-05Labeling · Supplement 18 · standardAP
2023-03-30Labeling · Supplement 14 · standardAP
2023-03-30Labeling · Supplement 13 · standardAP
2019-11-29Labeling · Supplement 8 · standardAP
2019-11-29Labeling · Supplement 6 · standardAP
2019-11-29Labeling · Supplement 2 · standardAP
2015-11-18UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →